Tibotec Pharmaceuticals Ltd
Unit 4 Block 4B
Blanchardstown Corporate Park
Blanchardstown
Dublin
15
Tel: 353-1-820-8114
Fax: 353-1-820-8082
Website: http://www.tibotec.be/
Email: info@tibbe.jnj.com
48 articles about Tibotec Pharmaceuticals Ltd
-
ChemDiv, Inc. Enters Into Research and Collaboration Agreement With Janssen Pharmaceutica N.V. and Tibotec Pharmaceuticals Ltd
12/20/2011
-
Bristol-Myers Squibb Company Enters Clinical Collaboration Agreement with Tibotec Pharmaceuticals Ltd for Phase II Combination Study in Patients Chronically Infected with Hepatitis C
12/2/2011
-
Gilead Sciences, Inc. Finalizes Agreement with Tibotec Pharmaceuticals Ltd to Develop and Commercialize a Single-Tablet Regimen of Prezista® with Emtriva®, GS 7340 and Cobicistat
11/16/2011
-
Gilead Sciences, Inc. and Johnson & Johnson's Tibotec Pharmaceuticals Ltd to Create Combination HIV Therapy
11/16/2011
-
Tibotec Pharmaceuticals Ltd to Present Final Safety and Efficacy Results From Phase 2b PILLAR Study of Once-Daily TMC435 in Late-Breaker at American Association for Study of Liver Diseases
11/7/2011
-
Tibotec Pharmaceuticals Ltd's EDURANT(R) (rilpivirine) Receives Positive Opinion from CHMP for Use in Treatment-Naive Adults with HIV-1
9/23/2011
-
Pharmasset, Inc. Enters into a Clinical Collaboration Agreement with Tibotec Pharmaceuticals Ltd for a Combination Study in Patients Chronically Infected with Hepatitis C
7/6/2011
-
Tibotec Pharmaceuticals Ltd Signs Multiple Agreements With Generic Manufacturers, Including Mylan Inc.'s Matrix Laboratories Limited, Aspen Pharmacare Holdings and Hetero Drugs to Provide Access to New HIV Treatment
1/27/2011
-
Tibotec Pharmaceuticals Ltd Submits New Drug Application for Investigational Once-Daily HIV Treatment TMC278 to U.S. FDA
7/26/2010
-
Tibotec Pharmaceuticals Ltd Announces TMC278 Pivotal Phase 3 Clinical Trials Achieve Primary Objective
7/23/2010
-
Gilead Sciences, Inc. Finalizes Selection of Bioequivalent Formulation for the Fixed-Dose Regimen of Truvada(R) and Tibotec Pharmaceuticals Ltd's TMC278
4/27/2010
-
Gilead Sciences, Inc. Provides Update on Development of Fixed-Dose Regimen of Truvada(R) and Tibotec Pharmaceuticals Ltd's TMC278
4/20/2010
-
Tibotec Pharmaceuticals Ltd Release: 96-Week Safety and Efficacy Findings Presented for INTELENCE(TM) (etravirine) As Part of HIV Combination Therapy
7/20/2009
-
Tibotec Pharmaceuticals Ltd and Centocor Ortho Biotech Inc. Release: New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U.S. HIV Clinical Studies
7/20/2009
-
Gilead Sciences, Inc. Announces Agreement With Tibotec Pharmaceuticals Ltd to Develop and Commercialize New Fixed-Dose Combination of Truvada and TMC278
7/17/2009
-
Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development
6/18/2009
-
Tibotec Pharmaceuticals Ltd and Emcure Pharmaceuticals Limited Collaborate on Access to Darunavir for India
12/3/2008
-
Tibotec Pharmaceuticals Ltd Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults
10/27/2008
-
Tibotec Pharmaceuticals Ltd Begins Enrollment for Phase III Study of Telaprevir, an Investigational Agent, in HCV Patients Who Failed Prior Treatment
10/15/2008
-
Tibotec Pharmaceuticals Ltd Conducts Two Pivotal Phase III Clinical Trials Studying TMC278 in Treatment-Naive Adults with HIV
7/17/2008